Inflammation and atherosclerosis: Group IIa and Group V sPLA2 are not redundant

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 26, Issue 7, 2006, Pages 1421-1422

  De Beer, Frederick C ^a,b   Webb, Nancy R ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; ISOENZYME; LOW DENSITY LIPOPROTEIN; PHOSPHOLIPASE A2; PROTEOGLYCAN; SECRETORY PHOSPHOLIPASE A2 SUBUNIT IIA; SECRETORY PHOSPHOLIPASE A2 SUBUNIT V; UNCLASSIFIED DRUG; GROUP II SECRETORY PHOSPHOLIPASE A2; PHOSPHOLIPASE A;

ATHEROGENESIS; ATHEROSCLEROSIS; CATABOLISM; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; DYSLIPIDEMIA; EDITORIAL; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME SUBUNIT; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; ISOENZYME ANALYSIS; LIPID STORAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; ENZYMOLOGY; METABOLISM; NOTE; PATHOPHYSIOLOGY;

ANIMALS; ATHEROSCLEROSIS; HUMANS; INFLAMMATION; ISOENZYMES; PHOSPHOLIPASES A;

EID: 33745959648     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000227561.89488.9a     Document Type: Editorial

References (13)

1. 2 in atherosclerosis and its potential as a therapeutic target. Curr Opin Pharmacol. 2006;6:154-161.
2. 2 group V: lesion distribution, activation by arterial proteoglycans, and induction in aorta by a Western diet. Arterioscler Thromb Vasc Biol. 2006;26:1579-1585.
3. Kugiyama K, Ota Y, Takazoe K, Moriyama Y, Kawano H, Miyao Y, Sakamoto T, Soejima H, Ogawa H, Doi H, Sugiyama S, Yasue H. Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease. Circulation. 1999;100:1280-1284.
4. 2 and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol. 2005;25:839-846.
5. Aarsman AJ, Neys FW, van der Helm HA, Kuypers FA, van den Bosch H. Sera of patients suffering from inflammatory diseases contain group IIA but not group V phospholipase A(2). Biochim Biophys Acta. 2000;1502:257-263.
6. 2. Arterioscler Thromb Vasc Biol. 1999;19:1284-1290.
7. 2 increases atherosclerotic lesion formation in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2003;23:263-268.
8. Gesquiere L, Cho W, Subbaiah PV. Role of group IIa and group V secretory phospholipases A(2) in the metabolism of lipoproteins. Substrate specificities of the enzymes and the regulation of their activities by sphingomyelin. Biochemistry. 2002;41:4911-4920.
9. Ishimoto Y, Yamada K, Yamamoto S, Ono T, Notoya M, Hanasaki K. Group V and X secretory phospholipase A(2)s-induced modification of high-density lipoprotein linked to the reduction of its antiatherogenic functions. Biochim Biophys Acta. 2003;1642:129-138.
10. 2 promotes SR-BI interaction and accelerates HDL metabolism. J Lipid Res. 2000;41:1849-1857.
11. 2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem. 2000;275:10077-10084.
12. Rye KA, Duong MN. Influence of phospholipid depletion on the size, structure, and remodeling of reconstituted high density lipoproteins. J Lipid Res. 2000;41:1640-1650.
13. 2-modified low density lipoprotein promotes foam cell formation by a SR-A- and CD36-independent process that involves cellular proteoglycans. J Biol Chem. 2005;280:32746-32752.